Immix Biopharma prices $125 million common stock offering

IMMX•2026-09-29

Immix Biopharma priced an underwritten offering of 11,363,637 shares at $11 per share, for $125 million. Net proceeds are intended to fund NXC-201 development, working capital and corporate purposes.

1. Offering details

Immix Biopharma priced an underwritten offering of 11,363,637 shares at $11 per share, totaling $125 million. The company said net proceeds will fund NXC-201 development, working capital and corporate purposes.

Immix Biopharma prices $125 million common stock offering

1. Offering details

Related News

Cognition Therapeutics schedules FDA meeting to align on Phase 3 DLB trial endpoints

IM Cannabis closes sale of IMC Holdings to Slil for C$3 million advance payment

TNL Mediagene unit Infobahn wins operational support role for TechGALA Japan 2026 conference

Medicus Pharma submits optimized teverelix protocol to FDA for advanced prostate cancer program

Barrington Research initiates coverage of Deluxe Corporation with Outperform rating, $31 target